CompareMarketResearchRequest a sample
Home / Healthcare / Gene Therapy

Healthcare · Market report

Gene Therapy Market Size, Share and Forecast 2026-2036

The global gene therapy market is worth USD 11.3 bn in 2026 and is forecast to reach USD 82.8 bn by 2036, growing at a 22.0% CAGR. United States is the largest country market and AAV vectors is the largest by vector segment.

USD 11.3 bnMarket size 2026
USD 82.8 bnForecast 2036
22.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global gene therapy market is worth USD 11.3 bn in 2026 and is forecast to reach USD 82.8 bn by 2036, growing at a 22.0% CAGR. United States is the largest country market and AAV vectors is the largest by vector segment.

ScopeGene therapies delivering or editing genetic material to treat disease, including AAV and lentiviral gene therapies and CRISPR-based treatments for rare, blood and neuromuscular disorders.
IndustryHealthcare
Value 2025USD 9.0 bn
Value 2026USD 11.3 bn
Value 2036USD 82.8 bn
CAGR 2026-203622.0%
Volume 202617.8 thousand patients
Volume 2036144 thousand patients
Average price 2026USD 636,400 per patient
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Gene Therapy market size and forecast, 2026-2036

Exhibit 1The global gene therapy market is forecast to grow from USD 11.3 bn in 2026 to USD 82.8 bn by 2036, more than five times its 2026 sizeGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 22.0%
Gene Therapy market value, 2025 to 2036Market value by year. 2025: USD 9.0 bn; 2026: USD 11.3 bn; 2027: USD 13.8 bn; 2028: USD 16.9 bn; 2029: USD 20.6 bn; 2030: USD 25.1 bn; 2031: USD 30.6 bn; 2032: USD 37.4 bn; 2033: USD 45.6 bn; 2034: USD 55.7 bn; 2035: USD 67.9 bn; 2036: USD 82.8 bn. Compound annual growth rate 2026 to 2036: 22.0%.202511.3 bn202630.6 bn203182.8 bn203622.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 11.3 bn
2027USD 13.8 bn
2028USD 16.9 bn
2029USD 20.6 bn
2030USD 25.1 bn
2031USD 30.6 bn
2032USD 37.4 bn
2033USD 45.6 bn
2034USD 55.7 bn
2035USD 67.9 bn
2036USD 82.8 bn

Gene Therapy market segmentation

By vector

Exhibit 2AAV vectors is the largest segment by vector, with 46.0% of 2026 revenueEstimated share of 2026 global revenue, by vector
Gene Therapy market share by vector, 2026Share of 2026 revenue by vector. AAV vectors: 46.0%; Lentiviral and other viral: 22.0%; Gene editing: 20.0%; Non-viral and others: 12.0%.AAV vectors46.0%Lentiviral and other viral22.0%Gene editing20.0%Non-viral and others12.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
AAV vectors46.0%34.4%USD 5.2 bn18.5%
Lentiviral and other viral22.0%17.9%USD 2.5 bn19.5%
Gene editing20.0%36.2%USD 2.3 bn29.5%
Non-viral and others12.0%11.5%USD 1.4 bn21.5%

By therapy area

Exhibit 3Hematology adds the most revenue by therapy area, growing from USD 3.2 bn in 2026 to USD 24.7 bn by 2036Estimated revenue in USD by therapy area, 2026 and 2036 forecast
Gene Therapy market by therapy area, 2026 and 2036Revenue by therapy area in 2026 and 2036. Hematology: USD 3.2 bn in 2026, USD 24.7 bn in 2036, change +678%; Neuromuscular: USD 3.9 bn in 2026, USD 19.7 bn in 2036, change +412%; Metabolic and other rare: USD 2.0 bn in 2026, USD 18.7 bn in 2036, change +816%; Oncology: USD 1.4 bn in 2026, USD 14.6 bn in 2036, change +975%; Ophthalmology: USD 907 mn in 2026, USD 5.1 bn in 2036, change +458%.20262036 forecastChangeHematology+678%3.2 bn24.7 bnNeuromuscular+412%3.9 bn19.7 bnMetabolic and other rare+816%2.0 bn18.7 bnOncology+975%1.4 bn14.6 bnOphthalmology+458%907 mn5.1 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Neuromuscular34.0%23.8%USD 3.9 bn17.7%
Hematology28.0%29.8%USD 3.2 bn22.8%
Ophthalmology8.0%6.1%USD 907 mn18.8%
Oncology12.0%17.7%USD 1.4 bn26.8%
Metabolic and other rare18.0%22.6%USD 2.0 bn24.8%

By delivery

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
In vivo52.0%56.0%USD 5.9 bn22.9%
Ex vivo40.0%36.0%USD 4.5 bn20.7%
Local direct injection8.0%8.0%USD 907 mn22.0%

By route of administration

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Intravenous48.0%46.0%USD 5.4 bn21.5%
Intrathecal and intracerebral16.0%20.0%USD 1.8 bn24.8%
Subretinal and intravitreal14.0%14.0%USD 1.6 bn22.0%
Intramuscular and local22.0%20.0%USD 2.5 bn20.8%

By end user

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Specialised treatment centres62.0%58.0%USD 7.0 bn21.2%
Hospitals30.0%32.0%USD 3.4 bn22.8%
Specialty clinics8.0%10.0%USD 907 mn24.8%

Top 25 countries for gene therapy by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 95.0% of 2026 revenue and the 25 countries below together hold 98.5%.

Exhibit 4United States is the largest country market at USD 6.6 bn in 2026, and the three largest countries hold 69.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Gene Therapy market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 6.6 bn, 58.0%; Germany: USD 680 mn, 6.0%; United Kingdom: USD 567 mn, 5.0%; France: USD 567 mn, 5.0%; Japan: USD 567 mn, 5.0%; Italy: USD 454 mn, 4.0%; China: USD 454 mn, 4.0%; Spain: USD 340 mn, 3.0%; Saudi Arabia: USD 340 mn, 3.0%; Canada: USD 227 mn, 2.0%.United States6.6 bn 58.0%Germany680 mn 6.0%United Kingdom567 mn 5.0%France567 mn 5.0%Japan567 mn 5.0%Italy454 mn 4.0%China454 mn 4.0%Spain340 mn 3.0%Saudi Arabia340 mn 3.0%Canada227 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 6.6 bn58.0%USD 43.7 bn20.9%
2GermanyUSD 680 mn6.0%USD 5.3 bn22.8%
3United KingdomUSD 567 mn5.0%USD 4.1 bn21.8%
4FranceUSD 567 mn5.0%USD 4.5 bn22.9%
5JapanUSD 567 mn5.0%USD 4.1 bn21.8%
6ItalyUSD 454 mn4.0%USD 3.3 bn22.0%
7ChinaUSD 454 mn4.0%USD 6.2 bn29.9%
8SpainUSD 340 mn3.0%USD 2.7 bn22.8%
9Saudi ArabiaUSD 340 mn3.0%USD 3.4 bn25.9%
10CanadaUSD 227 mn2.0%USD 1.5 bn20.7%
11SwitzerlandUSD 46 mn0.4%USD 306 mn20.8%
12NetherlandsUSD 41 mn0.4%USD 265 mn20.6%
13AustraliaUSD 34 mn0.3%USD 232 mn21.2%
14BelgiumUSD 34 mn0.3%USD 232 mn21.2%
15South KoreaUSD 28 mn0.2%USD 240 mn23.8%
16SwedenUSD 28 mn0.2%USD 191 mn21.0%
17BrazilUSD 23 mn0.2%USD 191 mn23.7%
18AustriaUSD 23 mn0.2%USD 149 mn20.7%
19DenmarkUSD 23 mn0.2%USD 149 mn20.7%
20IsraelUSD 23 mn0.2%USD 149 mn20.7%
21United Arab EmiratesUSD 23 mn0.2%USD 191 mn23.7%
22IndiaUSD 17 mn0.1%USD 174 mn26.2%
23TurkeyUSD 17 mn0.1%USD 141 mn23.5%
24PolandUSD 17 mn0.1%USD 116 mn21.2%
25QatarUSD 17 mn0.1%USD 141 mn23.5%
Rest of worldUSD 174 mn1.5%USD 1.3 bn22.1%
Exhibit 5United States and China account for 60% of the USD 71.5 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Gene Therapy market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 11.3 bn. United States: +USD 37.2 bn; China: +USD 5.8 bn; Germany: +USD 4.6 bn; France: +USD 3.9 bn; United Kingdom: +USD 3.5 bn; 20 other countries: +USD 15.5 bn; Rest of world: +USD 1.1 bn. Market value 2036: USD 82.8 bn.Market value 202611.3 bnUnited States+37.2 bnChina+5.8 bnGermany+4.6 bnFrance+3.9 bnUnited Kingdom+3.5 bn20 other countries+15.5 bnRest of world+1.1 bnMarket value 203682.8 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Novartis
  • Vertex Pharmaceuticals
  • Sarepta Therapeutics
  • Pfizer
  • CSL
  • Roche
  • BioMarin Pharmaceutical
  • Bayer

Group 2: Regional and specialist players

  • Ultragenyx
  • PTC Therapeutics
  • Krystal Biotech
  • uniQure
  • Orchard Therapeutics
  • Ferring Pharmaceuticals
  • REGENXBIO
  • Abeona Therapeutics
  • MeiraGTx

Group 3: Emerging and niche players

  • CRISPR Therapeutics
  • Intellia Therapeutics
  • Beam Therapeutics
  • Rocket Pharmaceuticals
  • Solid Biosciences
  • Voyager Therapeutics
  • Sangamo Therapeutics
  • Editas Medicine
  • 4D Molecular Therapeutics

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the gene therapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 22.0% is calculated from the resulting values.

The market is divided by vector, by therapy area, by delivery, by route of administration, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the gene therapy market?

The global gene therapy market is estimated at USD 9.0 bn in 2025 and USD 11.3 bn in 2026.

How fast will the gene therapy market grow?

It is forecast to reach USD 82.8 bn by 2036, a compound annual growth rate of 22.0% from 2026, an increase of USD 71.5 bn.

Which country is the largest market for gene therapy?

United States is the largest market by revenue at USD 6.6 bn in 2026, 58.0% of the global total. The three largest countries together hold 69.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 29.9% a year from 2026 to 2036.

Which gene therapy segment is largest?

In the by vector split, AAV vectors is the largest segment with 46.0% of 2026 revenue.

Who are the leading gene therapy companies?

Global leaders include Novartis, Vertex Pharmaceuticals, Sarepta Therapeutics, Pfizer.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Gene Synthesis Generic Drugs →

All Healthcare markets →

Request a sample